Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009942
Filing Date
2022-05-16
Accepted
2022-05-16 07:31:06
Documents
53
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tcrt-20220331.htm   iXBRL 10-Q 1718376
2 EX-31.1 tcrt-ex31_1.htm EX-31.1 15973
3 EX-32 tcrt-ex32.htm EX-32 7556
  Complete submission text file 0000950170-22-009942.txt   6051674

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tcrt-20220331_def.xml EX-101.DEF 268582
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tcrt-20220331_cal.xml EX-101.CAL 31011
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tcrt-20220331.xsd EX-101.SCH 56806
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tcrt-20220331_lab.xml EX-101.LAB 453409
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tcrt-20220331_pre.xml EX-101.PRE 354961
47 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20220331_htm.xml XML 749161
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 22925468
SIC: 2834 Pharmaceutical Preparations